{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T12:41:37Z","timestamp":1773232897880,"version":"3.50.1"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejmech.2025.118096","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T23:34:36Z","timestamp":1756251276000},"page":"118096","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Targeting melanoma resistance: Novel oxindole and non-oxindole-based benzimidazole derivatives as potent dual inhibitors of BRAFV600E and ABL2 kinases"],"prefix":"10.1016","volume":"300","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0145-7868","authenticated-orcid":false,"given":"Mohamed A.S.","family":"Badawy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Abdel-Aziz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamdy M.","family":"Abdel-Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taha F.S.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118096_bib1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3389\/fmolb.2020.00113","article-title":"The current state of molecular testing in the BRAF-mutated melanoma landscape","volume":"7","author":"Vanni","year":"2020","journal-title":"Front. Mol. Biosci."},{"issue":"7","key":"10.1016\/j.ejmech.2025.118096_bib2","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.3390\/ijms22073474","article-title":"BRAF gene and melanoma: back to the future","volume":"22","author":"Ottaviano","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118096_bib3","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118096_bib4","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2174\/1871520622666220624164152","article-title":"Current insights into the role of BRAF inhibitors in treatment of melanoma","volume":"23","author":"Singh","year":"2023","journal-title":"Anti Cancer Agents Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118096_bib5","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/CCO.0b013e3282f5271c","article-title":"The MAPK pathway in melanoma","volume":"20","author":"Fecher","year":"2008","journal-title":"Curr. Opin. Oncol."},{"issue":"12","key":"10.1016\/j.ejmech.2025.118096_bib6","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.3390\/cancers15123224","article-title":"New approaches to targeted therapy in melanoma","volume":"15","author":"Fernandez","year":"2023","journal-title":"Cancers"},{"issue":"13","key":"10.1016\/j.ejmech.2025.118096_bib7","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.3390\/ijms21134576","article-title":"Targeted therapy in melanoma and mechanisms of resistance","volume":"21","author":"Czarnecka","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118096_bib8","series-title":"Seminars in Cancer Biology","article-title":"RAF-MEK-ERK pathway in cancer evolution and treatment","author":"Ullah","year":"2022"},{"key":"10.1016\/j.ejmech.2025.118096_bib9","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/1079827","article-title":"Overcoming resistance to therapies targeting the MAPK pathway in BRAF-mutated tumours","volume":"2020","author":"Paton","year":"2020","journal-title":"J. Oncol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118096_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/1535370220959657","article-title":"Prevalence of class I\u2013III BRAF mutations among 114,662 cancer patients in a large genomic database","volume":"246","author":"Owsley","year":"2021","journal-title":"Exp. Biol. Med."},{"issue":"44","key":"10.1016\/j.ejmech.2025.118096_bib11","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.19836","article-title":"BRAF inhibitors: resistance and the promise of combination treatments for melanoma","volume":"8","author":"Griffin","year":"2017","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.ejmech.2025.118096_bib12","doi-asserted-by":"crossref","first-page":"237","DOI":"10.21037\/atm.2016.06.07","article-title":"Resistant mechanisms to BRAF inhibitors in melanoma","volume":"4","author":"Manzano","year":"2016","journal-title":"Ann. Transl. Med."},{"issue":"7","key":"10.1016\/j.ejmech.2025.118096_bib13","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1158\/1078-0432.CCR-13-3122","article-title":"BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact","volume":"20","author":"Rizos","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"19","key":"10.1016\/j.ejmech.2025.118096_bib14","doi-asserted-by":"crossref","first-page":"387","DOI":"10.21037\/atm.2017.06.09","article-title":"Overcoming resistance to BRAF inhibitors","volume":"5","author":"Arozarena","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ejmech.2025.118096_bib15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejca.2016.12.010","article-title":"The mitogen-activated protein kinase pathway in melanoma part I\u2013activation and primary resistance mechanisms to BRAF inhibition","volume":"73","author":"Amaral","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.118096_bib16","series-title":"Investigating the Metabolic and Therapeutic Effects of Combined Glutaminase and mutant-BRAF Inhibitors in Melanoma","author":"Harris","year":"2022"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118096_bib17","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2298\/AOO220130004C","article-title":"BRAF mutation in colorectal cancer: an update","volume":"29","author":"Colombo","year":"2023","journal-title":"Arch. Oncol."},{"key":"10.1016\/j.ejmech.2025.118096_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1067252","article-title":"Implications of BRAF V600E mutation in gliomas: molecular considerations, prognostic value and treatment evolution","volume":"12","author":"Di Nunno","year":"2023","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118096_bib19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/CMR.0000000000000630","article-title":"The clinical characteristics of melanoma with BRAF V600R mutation: a case series study","volume":"30","author":"Malkhasyan","year":"2020","journal-title":"Melanoma Res."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118096_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0230136","article-title":"BRAF V600E mutational load as a prognosis biomarker in malignant melanoma","volume":"15","author":"Sevilla","year":"2020","journal-title":"PLoS One"},{"issue":"20","key":"10.1016\/j.ejmech.2025.118096_bib21","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118096_bib22","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ejmech.2025.118096_bib23","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.trecan.2020.05.009","article-title":"Clinical development of BRAF plus MEK inhibitor combinations","volume":"6","author":"Subbiah","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ejmech.2025.118096_bib24","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2020.12.021","article-title":"Outcome of combination therapy using BRAF and MEK inhibitors among Asian patients with advanced melanoma: an analysis of 112 cases","volume":"145","author":"Fujisawa","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.118096_bib25","series-title":"Mechanisms of Resistance to BRAF and MEK Inhibitors in BRAF-mutant Melanoma","author":"Patel","year":"2022"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118096_bib26","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1038\/s41467-020-19075-3","article-title":"Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1\/2-mediated reactivation of MEK\/ERK\/MYC signaling","volume":"11","author":"Tripathi","year":"2020","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.ejmech.2025.118096_bib27","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1002\/1873-3468.14531","article-title":"The cross\u2010talk between Abl2 tyrosine kinase and TGF\u03b21 signalling modulates the invasion of clear cell renal cell carcinoma cells","volume":"597","author":"De Marco","year":"2023","journal-title":"FEBS Lett."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118096_bib28","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3390\/cancers12020482","article-title":"Current advances in the treatment of BRAF-mutant melanoma","volume":"12","author":"Patel","year":"2020","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.ejmech.2025.118096_bib29","doi-asserted-by":"crossref","first-page":"954","DOI":"10.3390\/cancers15030954","article-title":"ABL1\/2 and DDR1 drive MEKi resistance in NRAS-mutant melanomas by stabilizing RAF\/MYC\/ETS1 and promoting RAF homodimerization","volume":"15","author":"Lyon","year":"2023","journal-title":"Cancers"},{"issue":"32","key":"10.1016\/j.ejmech.2025.118096_bib30","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1038\/onc.2017.76","article-title":"Abl kinase regulation by BRAF\/ERK and cooperation with Akt in melanoma","volume":"36","author":"Jain","year":"2017","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118096_bib31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/jhet.4355","article-title":"Benzimidazole based derivatives as anticancer agents: structure activity relationship analysis for various targets","volume":"59","author":"Satija","year":"2022","journal-title":"J. Heterocycl. Chem."},{"issue":"35","key":"10.1016\/j.ejmech.2025.118096_bib32","doi-asserted-by":"crossref","first-page":"5970","DOI":"10.2174\/0929867326666190808122929","article-title":"Recent progress of Benzimidazole hybrids for anticancer potential","volume":"27","author":"Akhtar","year":"2020","journal-title":"Curr. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118096_bib33","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2174\/1385272825666210208141107","article-title":"Benzimidazole: a multifacted nucelus for anticancer agents","volume":"25","author":"Bansal","year":"2021","journal-title":"Curr. Org. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118096_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202200051","article-title":"Benzimidazole hybrids as anticancer drugs: an updated review on anticancer properties, structure\u2013activity relationship, and mechanisms of action (2019\u20132021)","volume":"355","author":"Feng","year":"2022","journal-title":"Arch. Pharmazie"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118096_bib35","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.apsb.2022.09.010","article-title":"Benzimidazole and its derivatives as cancer therapeutics: the potential role from traditional to precision medicine","volume":"13","author":"Lee","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118096_bib36","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2217\/fon.14.208","article-title":"Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity","volume":"11","author":"Porta","year":"2015","journal-title":"Future Oncol."},{"issue":"25","key":"10.1016\/j.ejmech.2025.118096_bib37","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118096_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.181","article-title":"Small molecule inhibitors targeting the cancers","volume":"3","author":"Liu","year":"2022","journal-title":"MedComm"},{"key":"10.1016\/j.ejmech.2025.118096_bib39","series-title":"Discovery and Development of Galeterone (TOK-001 or VN\/124-1) for the Treatment of all Stages of Prostate Cancer","author":"Njar","year":"2015"},{"key":"10.1016\/j.ejmech.2025.118096_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107243","article-title":"Benzimidazole-oxindole hybrids as multi-kinase inhibitors targeting melanoma","volume":"146","author":"Allam","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2025.118096_bib41","doi-asserted-by":"crossref","first-page":"5907","DOI":"10.1039\/D4RA00157E","article-title":"New pyrazolylindolin-2-one based coumarin derivatives as anti-melanoma agents: design, synthesis, dual BRAF V600E\/VEGFR-2 inhibition, and computational studies","volume":"14","author":"Sabt","year":"2024","journal-title":"RSC Adv."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118096_bib42","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1007\/s11030-023-10699-3","article-title":"An updated literature on BRAF inhibitors (2018\u20132023)","volume":"28","author":"Maji","year":"2024","journal-title":"Mol. Divers."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118096_bib43","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3390\/receptors3010005","article-title":"Role and function of receptor tyrosine kinases in BRAF mutant cancers","volume":"3","author":"Biersack","year":"2024","journal-title":"Receptor"},{"issue":"9","key":"10.1016\/j.ejmech.2025.118096_bib44","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.3390\/ijms25094633","article-title":"RAF and MEK inhibitors in non-small cell lung cancer","volume":"25","author":"Adamopoulos","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118096_bib45","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2024.35.e104","article-title":"Targeting BRAF pathway in low-grade serous ovarian cancer","volume":"35","author":"Perrone","year":"2024","journal-title":"Journal of Gynecologic Oncology"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118096_bib46","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/PPO.0000000000000702","article-title":"Investigational approaches for treatment of melanoma patients progressing after standard of care","volume":"30","author":"Fletcher","year":"2024","journal-title":"Cancer J."},{"key":"10.1016\/j.ejmech.2025.118096_bib47","article-title":"BRAFV600E-Mutant metastatic colorectal cancer: current evidence, future directions, and research priorities","author":"Piercey","year":"2024","journal-title":"Clin. Colorectal Cancer"},{"issue":"5","key":"10.1016\/j.ejmech.2025.118096_bib48","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.3390\/ijms25052956","article-title":"Regulation of cell cycle progression through RB phosphorylation by nilotinib and AT-9283 in human Melanoma A375P cells","volume":"25","author":"Pham","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.ejmech.2025.118096_bib49","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.3390\/biomedicines12081851","article-title":"Advances in melanoma: from genetic insights to therapeutic innovations","volume":"12","author":"Valdez-Salazar","year":"2024","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118096_bib50","article-title":"Impact of nintedanib and anti-angiogenic agents on uveal melanoma cell behavior","volume":"65","author":"Pawlik","year":"2024","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118096_bib51","article-title":"Isatin and its derivatives: review of pharmacological activities and therapeutic potential","volume":"20","author":"\u0417\u0430\u0439\u043a\u043e\u0432","year":"2024","journal-title":"Management & Education\/Upravlenie i Obrazovanie"},{"key":"10.1016\/j.ejmech.2025.118096_bib52","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for sunitinib","volume":"15","author":"Zhang","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118096_bib53","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1208\/s12249-024-02869-9","article-title":"Advanced delivery strategies of nintedanib for lung disorders and beyond: a comprehensive review","volume":"25","author":"Thakkar","year":"2024","journal-title":"AAPS PharmSciTech"},{"issue":"6","key":"10.1016\/j.ejmech.2025.118096_bib54","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1208\/s12249-024-02902-x","article-title":"Preparation, characterization and evaluation of nintedanib amorphous solid dispersions with enhanced oral bioavailability","volume":"25","author":"Liu","year":"2024","journal-title":"AAPS PharmSciTech"},{"issue":"12","key":"10.1016\/j.ejmech.2025.118096_bib55","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.3390\/molecules27123678","article-title":"Application of pharmacokinetic prediction platforms in the design of optimized anti-cancer drugs","volume":"27","author":"Beck","year":"2022","journal-title":"Molecules"},{"issue":"44","key":"10.1016\/j.ejmech.2025.118096_bib56","doi-asserted-by":"crossref","first-page":"27659","DOI":"10.1039\/D1RA04756F","article-title":"Design, synthesis, biological assessment and in silico ADME prediction of new 2-(4-(methylsulfonyl) phenyl) benzimidazoles as selective cyclooxygenase-2 inhibitors","volume":"11","author":"Badawy","year":"2021","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2025.118096_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105347","article-title":"Synthesis, in vitro anticancer activity and in silico studies of certain pyrazole-based derivatives as potential inhibitors of cyclin dependent kinases (CDKs)","volume":"116","author":"Mohammed","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118096_bib58","article-title":"Time-performance relationship and the associated mechanism of tumor drug-efflux pump P-glycoprotein reversal induced by mild photothermal therapy","author":"Shi","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejmech.2025.118096_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113403","article-title":"Discovery of new pyrimidopyrrolizine\/indolizine-based derivatives as P-glycoprotein inhibitors: design, synthesis, cytotoxicity, and MDR reversal activities","volume":"218","author":"Shawky","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"6690","key":"10.1016\/j.ejmech.2025.118096_bib60","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1126\/science.add9528","article-title":"Control of cell proliferation by memories of mitosis","volume":"383","author":"Meitinger","year":"2024","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.ejmech.2025.118096_bib61","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41419-024-06712-8","article-title":"Research progress on morphology and mechanism of programmed cell death","volume":"15","author":"Chen","year":"2024","journal-title":"Cell Death Dis."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118096_bib62","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41580-023-00689-6","article-title":"A guide to cell death pathways","volume":"25","author":"Yuan","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118096_bib63","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3390\/molecules28020776","article-title":"Evaluation of free online ADMET tools for academic or small biotech environments","volume":"28","author":"Dulsat","year":"2023","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118096_bib64","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3390\/futurepharmacol2020013","article-title":"In silico ADME profiling of salubrinal and its analogues","volume":"2","author":"Zadorozhnii","year":"2022","journal-title":"Future Pharmacology"},{"key":"10.1016\/j.ejmech.2025.118096_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2025.160423","article-title":"Minimizing late-stage failure in drug development with transformer models: enhancing drug screening and pharmacokinetic predictions","author":"Khambhawala","year":"2025","journal-title":"Chem. Eng. J."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118096_bib66","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.3390\/pharmaceutics15041212","article-title":"ADME, pharmacokinetic scaling, pharmacodynamic and prediction of human dose and regimen of novel antiviral drugs","volume":"15","author":"Chaira","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2025.118096_bib67","first-page":"1","article-title":"Pharmacokinetic\/pharmacodynamic considerations of alternate dosing strategies of tocilizumab in COVID-19","author":"Leung","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2025.118096_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2021.130337","article-title":"A newly synthesized small molecule: the evaluation against Alzheimer's disease by in silico drug design and computational structure analysis methods","volume":"1236","author":"\u015eahin","year":"2021","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ejmech.2025.118096_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106774","article-title":"Rule of five violations among the FDA-approved small molecule protein kinase inhibitors","volume":"191","author":"Roskoski","year":"2023","journal-title":"Pharmacol. Res."},{"issue":"11","key":"10.1016\/j.ejmech.2025.118096_bib70","doi-asserted-by":"crossref","DOI":"10.1002\/minf.202300115","article-title":"Absorption matters: a closer look at popular oral bioavailability rules for drug approvals","volume":"42","author":"Caminero Gomes Soares","year":"2023","journal-title":"Molecular informatics"},{"issue":"8","key":"10.1016\/j.ejmech.2025.118096_bib71","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.2174\/1570180820666230224112505","article-title":"Description and in silico ADME studies of US-FDA approved drugs or drugs under clinical trial which violate the Lipinski's rule of 5","volume":"21","author":"Lohit","year":"2024","journal-title":"Lett. Drug Des. Discov."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118096_bib72","doi-asserted-by":"crossref","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.ejmech.2025.118096_bib73","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202300244","article-title":"Novel hydrazone\u2010isatin derivatives as potential EGFR inhibitors: synthesis and in vitro pharmacological profiling","volume":"356","author":"Ahmed","year":"2023","journal-title":"Arch. Pharmazie"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118096_bib74","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3390\/molecules29020446","article-title":"Benzimidazole-based derivatives as apoptotic antiproliferative agents: design, synthesis, docking, and mechanistic studies","volume":"29","author":"Youssif","year":"2024","journal-title":"Molecules"},{"issue":"10","key":"10.1016\/j.ejmech.2025.118096_bib75","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202300721","article-title":"Benzimidazole\u2010oxindole hybrids: a novel class of selective dual CDK2 and GSK\u20103\u03b2 inhibitors of potent anticancer activity","volume":"357","author":"Abdel\u2010Mohsen","year":"2024","journal-title":"Arch. Pharmazie"},{"key":"10.1016\/j.ejmech.2025.118096_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108297","article-title":"New antiproliferative 1, 3, 4-oxadiazole\/benzimidazole derivatives: design, synthesis, and biological evaluation as dual EGFR and BRAFV600E inhibitors","author":"Hagar","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118096_bib77","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12964-021-00739-6","article-title":"Role of the ABL tyrosine kinases in the epithelial\u2013mesenchymal transition and the metastatic cascade","volume":"19","author":"Luttman","year":"2021","journal-title":"Cell Commun. Signal."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118096_bib78","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1158\/1535-7163.MCT-10-0799","article-title":"BRAFV600E: implications for carcinogenesis and molecular therapy","volume":"10","author":"Cantwell-Dorris","year":"2011","journal-title":"Mol. Cancer Therapeut."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118096_bib79","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3390\/ijms18030585","article-title":"Strategies for overcoming resistance in tumours harboring BRAF mutations","volume":"18","author":"Obaid","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"44","key":"10.1016\/j.ejmech.2025.118096_bib80","doi-asserted-by":"crossref","first-page":"30753","DOI":"10.1039\/D3RA05310E","article-title":"Pyrrolizine\/indolizine-bearing (un) substituted isoindole moiety: design, synthesis, antiproliferative and MDR reversal activities, and in silico studies","volume":"13","author":"AbdelSamad","year":"2023","journal-title":"RSC Adv."},{"issue":"1\u20132","key":"10.1016\/j.ejmech.2025.118096_bib81","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0166-0934(91)90008-N","article-title":"An application of tetrazolium (MTT) colorimetric assay for the screening of anti-herpes simplex virus compounds","volume":"33","author":"Takeuchi","year":"1991","journal-title":"J. Virol. Methods"},{"issue":"10","key":"10.1016\/j.ejmech.2025.118096_bib82","first-page":"2515","article-title":"Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production","volume":"51","author":"Vistica","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118096_bib83","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.88206","article-title":"Discovery and characterization of a specific inhibitor of serine-threonine kinase cyclin-dependent kinase-like 5 (CDKL5) demonstrates role in hippocampal CA1 physiology","volume":"12","author":"Castano","year":"2023","journal-title":"eLife"},{"issue":"7","key":"10.1016\/j.ejmech.2025.118096_bib84","doi-asserted-by":"crossref","DOI":"10.1002\/aoc.7129","article-title":"Newly synthesised schiff base metal complexes, characterisation, and contribution as enhancers of colon cancer cell apoptosis by overexpression of P53 protein","volume":"37","author":"Abd El\u2010Hamid","year":"2023","journal-title":"Appl. Organomet. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118096_bib85","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202300626","article-title":"Quinazoline\u2010chalcone hybrids as HDAC\/EGFR dual inhibitors: design, synthesis, mechanistic, and in\u2010silico studies of potential anticancer activity against multiple myeloma","volume":"357","author":"Mansour","year":"2024","journal-title":"Arch. Pharmazie"},{"key":"10.1016\/j.ejmech.2025.118096_bib86","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/978-1-0716-1278-1_17","article-title":"An annexin V-FITC\u2014propidium iodide-based method for detecting apoptosis in a non-small cell lung cancer cell line","author":"Kumar","year":"2021","journal-title":"Lung Cancer: Methods Protoc."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118096_bib87","doi-asserted-by":"crossref","DOI":"10.1515\/chem-2024-0083","article-title":"Antioxidant and antidiabetic potentials of methoxy-substituted schiff bases using in vitro, in vivo, and molecular simulation approaches","volume":"22","author":"Kashif","year":"2024","journal-title":"Open Chem."},{"key":"10.1016\/j.ejmech.2025.118096_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105883","article-title":"Design, synthesis and anticancer activity of novel 2-arylbenzimidazole\/2-thiopyrimidines and 2-thioquinazolin-4 (3H)-ones conjugates as targeted RAF and VEGFR-2 kinases inhibitors","volume":"126","author":"Ali","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118096_bib89","first-page":"1","article-title":"Comparative analysis of mangiferin against conventional drugs for skin cancer and inflammation: integrating in-silico and in-vitro studies","author":"Sharma","year":"2024","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.ejmech.2025.118096_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2023.137323","article-title":"Design, synthesis, and molecular docking of novel 1, 3, 4-triaryl pyrazole derivatives bearing methylsulfonyl moiety with anticancer activity through dual targeting CDK2 and COX-2 enzymes","volume":"1301","author":"Shaker","year":"2024","journal-title":"J. Mol. Struct."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118096_bib91","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10664-024-10557-2","article-title":"User feedback in continuous software engineering: revealing the state-of-practice","volume":"30","author":"Tkalich","year":"2025","journal-title":"Empir. Softw. Eng."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342500861X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342500861X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T15:14:32Z","timestamp":1760022872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352342500861X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":91,"alternative-id":["S022352342500861X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118096","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting melanoma resistance: Novel oxindole and non-oxindole-based benzimidazole derivatives as potent dual inhibitors of BRAFV600E and ABL2 kinases","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118096","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118096"}}